Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 8, 2016, Pages 893-905

  Sahin, Ibrahim H ^a   Lowery, Maeve A ^b,c   Stadler, Zsofia K ^b,c   Salo Mullen, Erin ^b   Iacobuzio Donahue, Christine A ^b   Kelsen, David P ^b,c   O’Reilly, Eileen M ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ARID1; ATM; BRCA1; BRCA2; cisplatin; DNA repair; genomic instability; MSH; PALB2; Pancreatic cancer; PARP inhibitors; PARP1; synthetic lethality

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CEP 9722; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INIPARIB; INO 1001; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NIRAPARIB; OLAPARIB; OXALIPLATIN; RUCAPARIB; TALAZOPARIB; TOPOTECAN; VELIPARIB; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TUMOR MARKER;

ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CELL CYCLE; DIARRHEA; DNA DAMAGE; DNA FINGERPRINTING; DNA REPAIR; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HEADACHE; HUMAN; HYPONATREMIA; INTESTINE PERFORATION; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; VOMITING; ADENOCARCINOMA; ANIMAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MUTATION; PANCREAS TUMOR; PATHOLOGY; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; MUTATION; PANCREATIC NEOPLASMS; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS;

EID: 84959236648     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1153424     Document Type: Review

References (80)

1. T.Conroy, F.Desseigne, M.Ychou, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med. 2011;364(19):1817–1825.
2. D.D.Von Hoff, T.Ervin, F.P.Arena, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med. 2013;369(18):1691–1703.
3. L.Rahib, B.D.Smith, R.Aizenberg, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
4. D.Li, K.Xie, R.Wolff, et al. Pancreatic cancer. Lancet. 2004;363(9414):1049–1057.
5. R.H.Hruban Familial pancreatic cancer. Arch Pathol Lab Med. 2009;133(3):365.
6. A.V.Biankin, N.Waddell, K.S.Kassahn, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405.
7. L.B.Alexandrov, S.Nik-Zainal, D.C.Wedge, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.•This study elucidated an overlapping signature model for breast, ovarian, and pancreatic cancer which was associated with germline BRCA mutations. This model was related to microhomology at rearrangements junctions.
8. P.J.Campbell, S.Yachida, L.J.Mudie, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467(7319):1109–1113.•This paper first demonstrated dynamic genomic alterations causing driver mutations in different metastatic foci.
9. S.Yachida, S.Jones, I.Bozic, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–1117.
10. N.Waddell, M.Pajic, A.-M.Patch, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.••This study identified that an unstable genomic pattern was associated with impaired DNA repair pathways in pancreatic cancer.
11. S.Jones, X.Zhang, D.W.Parsons, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806.
12. A.K.Witkiewicz, E.A.McMillan, U.Balaji, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6.
13. S.Negrini, V.G.Gorgoulis, T.D.Halazonetis. Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220–228.
14. P.A.Futreal, Q.Liu, D.Shattuck-Eidens, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266(5182):120–122.
15. K.Gudmundsdottir, A.Ashworth. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864–5874.
16. H.Song, M.Hollstein, Y.Xu. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9(5):573–580.
17. D.Cortez, Y.Wang, J.Qin, et al. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 1999;286(5442):1162–1166.
18. R.M.Marión, K.Strati, H.Li, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009;460(7259):1149–1153.
19. K.Fukasawa, F.Wiener, W.G.Vande, et al. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene. 1997;15(11):1295–1302.
20. S.Popat, R.Hubner, R.Houlston. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–618.
21. A.Hemminki, J.P.Mecklin, H.Järvinen, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology. 2000;119(4):921–928.
22. R.Gryfe, H.Kim, E.T.Hsieh, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. New Engl J Med. 2000;342(2):69–77.
23. D.T.Le, J.N.Uram, H.Wang, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.••This paper reported a benefit to checkpoint inhibitor therapy in defective DNA repair caused by mismatch repair deficiency in cancer patients.
24. A.Walther, R.Houlston, I.Tomlinson. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut. 2008;57:941–950.
25. N.R.Dos Santos, R.Seruca, M.Constância, et al. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology. 1996;110(1):38–44.
26. N.J.Roberts, Y.Jiao, J.Yu, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–46.
27. S.Banin, L.Moyal, S.-Y.Shieh, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281(5383):1674–1677.
28. M.E.Moynahan, J.W.Chiu, B.H.Koller, et al. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4(4):511–518.
29. S.N.Powell, L.A.Kachnic. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003;22(37):5784–5791.
30. S.Jones, R.H.Hruban, M.Kamiyama, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324(5924):217–217.
31. X.Li, W.-D.Heyer. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18(1):99–113.
32. N.Turner, A.Tutt, A.Ashworth. Hallmarks of’BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–819.
33. I.Hedenfalk, D.Duggan, Y.Chen, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344(8):539–548.•This article first described “BRCAness” pattern in BRCA mutant breast cancer patients.
34. T.Golan, Z.Kanji, R.Epelbaum, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111(6):1132–1138.•This study suggested a clinical benefit with use of platinum-based agents in BRCA mutant pancreatic cancer patients.
35. S.-M.Ee, O.Em, K.Dp, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015.
36. M.Y.Kim, T.Zhang, W.L.Kraus. Poly(ADP-ribosyl)ation by PARP-1:PAR-laying’NAD+ into a nuclear signal. Genes Dev. 2005;19(17):1951–1967.
37. K.W.Caldecott. Single-strand break repair and genetic disease. Nat Rev Genet. 2008;9(8):619–631.
38. M.L.Hegde, T.K.Hazra, S.Mitra. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 2008;18(1):27–47.
39. M.Wang, W.Wu, W.Wu, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34(21):6170–6182.
40. H.Hochegger, D.Dejsuphong, T.Fukushima, et al. Parp‐1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. Embo J. 2006;25(6):1305–1314.
41. P.Domagala, T.Huzarski, J.Lubinski, et al. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat. 2011;127(3):861–869.
42. H.E.Bryant, N.Schultz, H.D.Thomas, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature. 2005;434(7035):913–917.••This article demonstrated the rationale of using PARP inhibitors in cancer cells with defective DNA.
43. H.Farmer, N.McCabe, C.J.Lord, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921.
44. S.Lal, R.A.Burkhart, N.Beeharry, et al. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res. 2014;74(4):1128–1140.
45. D.Karnak, C.G.Engelke, L.A.Parsels, et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res. 2014;20(19):5085–5096.
46. S.Vance, E.Liu, L.Zhao, et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle. 2011;10(24):4321–4329.
47. M.A.Morgan, L.A.Parsels, L.Zhao, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 2010;70(12):4972–4981.
48. J.Shen, Y.Peng, L.Wei, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5(7):752–767.
49. J.Iqbal, A.Ragone, J.Lubinski, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005–2009.
50. D.Thompson, D.F.Easton, B.C.L.Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358–1365.
51. S.A.Hahn, B.Greenhalf, I.Ellis, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95(3):214–221.
52. J.P.Struewing, P.Hartge, S.Wacholder, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med. 1997;336(20):1401–1408.
53. Z.K.Stadler, E.Salo‐Mullen, S.M.Patil, et al. Prevalence of brca1 and brca2 mutations in ashkenazi jewish families with breast and pancreatic cancer. Cancer. 2012;118(2):493–499.
54. S.Holter, A.Borgida, A.Dodd, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015. doi:10.1200/JCO.2014.2059.7401.•This report provides a detailed study of germline BRCA in a cohort of patients with pancreas cancer.
55. P.C.Fong, D.S.Boss, T.A.Yap, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134.
56. J.Samol, M.Ranson, E.Scott, et al. Safety and tolerability of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs. 2012;30(4):1493–1500.
57. B.Kaufman, R.Shapira-Frommer, R.K.Schmutzler, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2014. doi:10.1200/JCO.2014.2056.2728.
58. J.Ledermann, P.Harter, C.Gourley, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Engl J Med. 2012;366(15):1382–1392.
59. S.K.Sandhu, W.R.Schelman, G.Wilding, et al. The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–892.
60. J.Berlin, R.K.Ramanathan, J.H.Strickler et al. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors. In: J Clin Oncol. 2014;32(5s):Abstract 2574.
61. M.J.Pishvaian, H.Wang, T.Zhuang, et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). J Clin Oncol. 2013;31(Supp 4):Abstract 147.
62. E.O’Reilly, M.Lowery, M.Segal, et al. Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). J Clin Oncol. 2014;32:5s.
63. D.R.Fogelman, R.A.Wolff, S.Kopetz, et al. Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. Anticancer Res. 2011;31(4):1417–1420.
64. M.L.Telli, K.C.Jensen, S.Vinayak, et al. Phase II Study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation–associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015. doi:10.1200/JCO.2014.2057.0085.
65. J.O’Shaughnessy, C.Osborne, J.E.Pippen, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205–214.
66. J.O’Shaughnessy, L.Schwartzberg, M.A.Danso, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32(34):3840–3847.
67. A.G.Patel, S.B.De Lorenzo, K.S.Flatten, et al. Failure of iniparib to inhibit poly (ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012;18(6):1655–1662.
68. M.A.Lowery, D.P.Kelsen, S.C.Smith et al. Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC). J Clin Oncol. 2015;33(Suppl 3):Abstract 358.
69. L.A.Carey. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J Clin Oncol. 2010;28(3):361–363.
70. I.Cass, R.L.Baldwin, T.Varkey, et al. Improved survival in women with BRCA‐associated ovarian carcinoma. Cancer. 2003;97(9):2187–2195.
71. M.A.Lowery, D.P.Kelsen, Z.K.Stadler, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16(10):1397–1402.
72. W.Sakai, E.M.Swisher, C.Jacquemont, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009;69(16):6381–6386.
73. W.Sakai, E.M.Swisher, B.Y.Karlan, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451(7182):1116–1120.
74. B.Norquist, K.A.Wurz, C.C.Pennil, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008–3015.
75. N.Johnson, S.F.Johnson, W.Yao, et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci USA. 2013;110(42):17041–17046.
76. N.Shafee, C.R.Smith, S.Wei, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53–mediated mouse mammary tumors. Cancer Res. 2008;68(9):3243–3250.
77. P.C.Fong, T.A.Yap, D.S.Boss, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512–2519.
78. L.B.Travis, E.J.Holowaty, K.Bergfeldt, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. New Engl J Med. 1999;340(5):351–357.
79. C.J.Lee, J.Dosch, D.M.Simeone. Pancreatic cancer stem cells. J Clin Oncol. 2008;26(17):2806–2812.
80. L.A.Chantrill, et al. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res. 2015;21:2029–2037. doi:10.1158/1078-0432.CCR-15-0426.